Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
25
07
2022
accepted:
20
10
2022
revised:
12
10
2022
pubmed:
15
11
2022
medline:
1
2
2023
entrez:
14
11
2022
Statut:
ppublish
Résumé
The real-world efficacy and safety of gilteritinib was assessed in an ambispective study that included 167 R/R FLT3-mutated AML patients. Among them, 140 received gilteritinib as single agent (cohort B), including 67 previously treated by intensive chemotherapy and midostaurin (cohort C). The main differences in patient characteristics in this study compared to the ADMIRAL trial were ECOG ≥ 2 (83.6% vs. 16.6%), FLT3-TKD mutation (21.0% vs. 8.5%), primary induction failure (15.0% vs. 40.0%) and line of treatment (beyond 2nd in 37.1% vs. 0.0%). The rates of composite complete remission, excluding those that occurred after hematopoietic stem cell transplantation (HSCT), were similar at respectively 25.4% and 27.5% in cohorts B and C. Median overall survival (OS) for these two groups was also similar at respectively 6.4 and 7.8 months. Multivariate analyses for prognostic factors associated with OS identified female gender (HR 1.61), adverse cytogenetic risk (HR 2.52), and allogenic HSCT after gilteritinib (HR 0.13). Although these patients were more heavily pretreated, these real-world data reproduce the results of ADMIRAL and provide new insights into the course of patients previously treated by intensive chemotherapy and midostaurin and beyond the 2nd line of treatment who can benefit from treatment in an outpatient setting.
Identifiants
pubmed: 36376378
doi: 10.1038/s41375-022-01742-7
pii: 10.1038/s41375-022-01742-7
doi:
Substances chimiques
midostaurin
ID912S5VON
gilteritinib
0
Staurosporine
H88EPA0A3N
fms-Like Tyrosine Kinase 3
EC 2.7.10.1
FLT3 protein, human
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
91-101Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Bullinger L, Döhner K, Döhner H. Genomics of acute myeloid leukemia diagnosis and pathways. J Clin Oncol J Am Soc Clin Oncol. 2017;35:934–46.
doi: 10.1200/JCO.2016.71.2208
Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N. Engl J Med. 2008;358:1909–18.
doi: 10.1056/NEJMoa074306
Smith CC, Wang Q, Chin C-S, Salerno S, Damon LE, Levis MJ, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012;485:260–3.
doi: 10.1038/nature11016
Cocciardi S, Dolnik A, Kapp-Schwoerer S, Rücker FG, Lux S, Blätte TJ, et al. Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. Nat Commun. 2019;10:2031.
doi: 10.1038/s41467-019-09745-2
Schmalbrock LK, Dolnik A, Cocciardi S, Sträng E, Theis F, Jahn N, et al. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood. 2021;137:3093–104.
doi: 10.1182/blood.2020007626
Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100:59–66.
doi: 10.1182/blood.V100.1.59
Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.
doi: 10.1182/blood-2016-08-733196
Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-Mutated AML. N. Engl J Med. 2019;381:1728–40.
doi: 10.1056/NEJMoa1902688
Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation. N Engl J Med 2017. https://doi.org/10.1056/NEJMoa1614359 .
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.
doi: 10.1182/blood-2016-03-643544
Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood. 1998;92:2322–33.
doi: 10.1182/blood.V92.7.2322
Numan Y, Abdel Rahman Z, Grenet J, Boisclair S, Bewersdorf JP, Collins C, et al. Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors. Am J Hematol. 2022;97:322–8.
doi: 10.1002/ajh.26447
Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017. https://doi.org/10.1016/S1470-2045(17)30416-3 .
Perl AE, Hosono N, Montesinos P, Podoltsev N, Martinelli G, Panoskaltsis N, et al. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. Blood Cancer J. 2022;12:84.
doi: 10.1038/s41408-022-00677-7
Wiernik PH, Sun Z, Cripe LD, Rowe JM, Fernandez HF, Luger SM, et al. Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia. Br J Haematol. 2021;194:309–18.
doi: 10.1111/bjh.17523
Dumas P-Y, Naudin C, Martin-Lannerée S, Izac B, Casetti L, Mansier O, et al. Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5- and hypoxia- dependent up-regulation of AXL. Haematologica 2019. https://doi.org/10.3324/haematol.2018.205385 .
Dumas P-Y, Villacreces A, Guitart AV, Ali EH, Massara L, Mansier O, et al. Dual inhibition of FLT3 and AXL by gilteritinib overcomes hematopoietic niche-driven resistance mechanisms in FLT3-ITD acute myeloid leukemia. Clin Cancer Res Off J Am Assoc Cancer Res. 2021; clincanres.3114.2020.
McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJD, Eastburn DJ, et al. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov. 2019;9:1050–63.
doi: 10.1158/2159-8290.CD-18-1453
Smith CC, Levis MJ, Perl AE, Hill JE, Rosales M, Bahceci E. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6:2144–55.
doi: 10.1182/bloodadvances.2021006489
Joshi SK, Nechiporuk T, Bottomly D, Piehowski PD, Reisz JA, Pittsenbarger J, et al. The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance. Cancer Cell. 2021;39:999–1014.e8.
doi: 10.1016/j.ccell.2021.06.003
Pratz KW, Cherry M, Altman JK, Cooper BW, Cruz JC, Jurcic JG, et al. A Phase 1 Study of Gilteritinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed AML: Final results. Blood. 2020;136:16–17.
doi: 10.1182/blood-2020-137685
Wang ES, Montesinos P, Minden MD, Lee J-H, Heuser M, Naoe T, et al. Phase 3, open-label, randomized study of Gilteritinib and Azacitidine vs. Azacitidine for newly diagnosed FLT3-mutated acute myeloid leukemia in patients ineligible for intensive induction chemotherapy. Blood. 2021;138:700.
doi: 10.1182/blood-2021-145379
Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow MR, et al. Venetoclax in combination with gilteritinib demonstrates molecular clearance of FLT3 mutation in relapsed/Refractory FLT3-mutated acute myeloid leukemia. Blood. 2021;138:691.
doi: 10.1182/blood-2021-150743
Short NJ, DiNardo CD, Daver N, Nguyen D, Yilmaz M, Kadia TM, et al. A triplet combination of Azacitidine, Venetoclax and Gilteritinib for patients with FLT3-mutated acute myeloid leukemia: results from a Phase I/II Study. Blood. 2021;138:696.
doi: 10.1182/blood-2021-153571
Altman JK, Bhatnagar B, Abedin S, Przespolewski A, Patel PA, Schiller GJ, et al. Gilteritinib can be safely combined with Atezolizumab for the treatment of relapsed or refractory FLT3-mutated AML: Results of a Phase 1 Study. Blood. 2021;138:2343.
doi: 10.1182/blood-2021-150707